Market Overview

Second Sight to Present at Investor Conferences in September

Share:

Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or
"the Company"), a developer, manufacturer and marketer of implantable
visual prosthetics that are intended to create an artificial form of
useful vision to blind patients, today announced that Will McGuire,
President and Chief Executive Officer, and John Blake, Chief Financial
Officer, are scheduled to present at two upcoming conferences as follows:

Annual B. Riley FBR Healthcare Conference
Date: Tuesday,
September 4, 2018
Format: One-on-one investor meetings
Location:
New York Marriott East Side, 525 Lexington Avenue, NYC

H.C. Wainwright 20th Annual Global Investment Conference
Date:
Thursday, September 6, 2018
Presentation Time: 12:30 p.m. Eastern
Daylight Time
Location: The St. Regis New York, Two East 55th
Street, NYC
Webcast: http://wsw.com/webcast/rrshq28/eyes/

The presentation will be webcast live at the aforementioned time, and
archived for 30 days thereafter, via the Company's website at www.secondsight.com,
under the Investor Relations section.

Conference participation is by invitation only and registration is
mandatory. For more information or to schedule a one-on-one meeting,
please contact your B. Riley FBR or H.C. Wainwright representative.

About Second Sight

Second Sight Medical Products, Inc. develops, manufactures and markets
implantable visual prosthetics that are intended to deliver useful
artificial vision to blind individuals. Second Sight has developed, and
now manufactures and markets, the Argus® II Retinal Prosthesis System.
Development of new hardware and software intended to improve the quality
of the vision produced by the Argus system is ongoing. Second Sight is
also developing the Orion™ Visual Cortical Prosthesis to potentially
restore some vision to individuals who are blind due to many causes
other than preventable or treatable conditions. Second Sight's U.S.
headquarters are in Los Angeles, California, and European headquarters
are in Lausanne, Switzerland. For more information, please visit www.secondsight.com.

About the Argus II Retinal Prosthesis System

Second Sight's Argus II System provides electrical stimulation that
bypasses defunct retinal cells and stimulates remaining viable cells
inducing visual perception in individuals with severe to profound
retinitis pigmentosa (RP). The Argus II works by converting images
captured by a miniature video camera mounted on the patient's glasses
into a series of small electrical pulses, which are transmitted
wirelessly to an array of electrodes implanted on the surface of the
retina. These pulses stimulate the retina's remaining cells, intending
to result in the perception of patterns of light in the brain. The
patient must learn to interpret these visual patterns, having the
potential to regain some visual function. The Argus II is the first
artificial retina to receive widespread commercial approval, and is
offered at approved centers in Canada, France, Germany, Iran, Italy,
Russia, Saudi Arabia, Singapore, South Korea, Spain, Taiwan, Turkey, the
United Kingdom, and the United States. Further information on the
long-term benefits and risks can be found in the peer reviewed paper at: http://www.sciencedirect.com/science/article/pii/S0161642016305796

About the Orion Visual Cortical Prosthesis System

Like the Argus II, the Orion converts images captured by a miniature
video camera mounted on the patient's glasses into a series of small
electrical pulses. The Orion is designed to transmit these electrical
pulses wirelessly to an array of electrodes implanted on the surface of
the visual cortex, intended to result in the perception of patterns of
light. By bypassing the retina and optic nerve and directly stimulating
the visual cortex, a cortical prosthesis system has the potential to
restore useful vision to many more patients than the Argus II, including
patients completely blinded due to many reasons, including glaucoma,
diabetic retinopathy, or forms of cancer and trauma. The Company is
currently conducting a feasibility study in the U.S. at two centers: the
Ronald Reagan UCLA Medical Center and Baylor College of Medicine in
Houston. No published clinical data is yet available for the Orion.

Safe Harbor

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange and Exchange Act of 1934, as
amended, which are intended to be covered by the "safe harbor" created
by those sections. All statements in this release that are not based on
historical fact are "forward looking statements." These statements may
be identified by words such as "estimates," "anticipates," "projects,"
"plans," "goal," or "planned," "seeks," "may," "will," "expects,"
"intends," "believes," "should," and similar expressions, or the
negative versions thereof, and which also may be identified by their
context. All statements that address operating performance or events or
developments that Second Sight expects or anticipates will occur in the
future, such as stated objectives or goals, or that are not otherwise
historical facts, are forward-looking statements. While management has
based any forward-looking statements included in this release on its
current expectations, the information on which such expectations were
based may change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially from
those in the forward-looking statements, as a result of various factors
including those risks and uncertainties described in the Risk Factors
and in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our Annual Report, on Form 10-K, filed
on March 20, 2018, our most recent 10-Q, filed on August 7, 2018 and our
other reports filed from time to time with the Securities and Exchange
Commission. We urge you to consider those risks and uncertainties in
evaluating our forward-looking statements. We caution readers not to
place undue reliance upon any such forward-looking statements, which
speak only as of the date made. Except as otherwise required by the
federal securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in our
expectations with regard thereto, or any change in events, conditions,
or circumstances on which any such statement is based.

View Comments and Join the Discussion!